XML 122 R76.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Other operating expenses (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Analysis of income and expense [abstract] |
Schedule Other Operating Expenses | For 2023, this line item includes €3,206 million of expenses related to Regeneron (see Note C.1.), compared with €2,378 million for 2022 and €1,568 million for 2021 (as shown in the table below):
(€ million) | 2023 | 2022 | 2021
Income & expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance | (3,321) |  | (2,325) |  | (1,253) |
Additional share of profit paid by Regeneron towards development costs(b) | 668 |  | 434 |  | 127 |
Reimbursement to Regeneron of selling expenses incurred | (543) |  | (476) |  | (303) |
Total - Monoclonal Antibody Alliance | (3,196) |  | (2,367) |  | (1,429) |
Immuno-Oncology Alliance | — |  | 16 |  | 68 |
Other (mainly ZALTRAP and LIBTAYO)(a) | 217 |  | 1,120 |  | (12) |
Other operating income/(expenses), net related to Regeneron | (2,979) |  | (1,231) |  | (1,373) |
of which amount presented in Other operating income (Note D.25.) | 227 |  | 1,147 |  | 195 |
(a) Following the restructuring of the Immuno-Oncology agreement between Sanofi and Regeneron, applicable from July 1, 2022 (see Note C.1.). (b) As of December 31, 2023, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to €2.1 billion, compared with €2.7 billion as of December 31, 2022 (see note D.21.

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other Operating Expenses [Table Text Block] + References No definition available. + Details
Name: | sny_OtherOperatingExpensesTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration